AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUL 152 min read$PCVX

Vaxcyte, Inc. (PCVX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pcvx-20260713 0001649094 FALSE 825 Industrial Road Suite 300 San Carlos California 0001649094 2026-07-13 2026-07-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________________________ FORM 8-K _____________________________________

Original reporting
SEC EDGAR 8-K
Published Jul 15, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$PCVX
Neutral
medium confidence
Mentioned
$PCVX
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PCVXNeutralLow
01

Why it matters

The disclosure updates board membership and committee composition effective July 16, 2026, without indicating any disagreement, dispute, or related-party transactions.

02

Market read

Primarily governance housekeeping; traders may monitor for any subsequent proxy/committee-related disclosures but there is no operational catalyst here.

03

What to watch

The only potentially market-relevant detail is the new director’s committee assignments (Audit and Compensation), but no rationale or strategic shift is stated.

Relevance 6/10Novelty 3/10Timing: effective July 16, 2026, with 8-K filed July 15, 2026

Background

This is an SEC Form 8-K under Item 5.02 covering director retirement and appointment, plus non-employee director compensation details.

Company-level read

Ticker impact

$PCVXNeutralMedium confidence
Context

Vaxcyte disclosed a board change, with director Heath Lukatch retiring and John Markels appointed effective July 16, 2026.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to governance sentiment.

Evidence & confidence

The filing is a routine 8-K governance update. It does not disclose disputes, transactions, or operational guidance changes, only director appointment and compensation details.

Market effects

Sector

Minimal. Director/committee changes do not typically reset sector expectations.

Regional

Minimal, US-listed Nasdaq governance update.

Global

Minimal.

Counterpoint

What could challenge this read

If Markels’ background aligns with audit or compensation priorities, the change could signal internal governance tightening, but the filing provides no such specifics.

Key entities

  • issuer
    Vaxcyte, Inc.

    Nasdaq-listed company filing the 8-K regarding director retirement and appointment.

  • director
    Heath Lukatch

    Retiring board member, retirement effective July 16, 2026.

  • director
    John Markels

    Appointed Class II director effective July 16, 2026, and assigned to Audit and Compensation committees.

Read at source← All news

Related articles

AUG 5
$PCVXMed

Vaxcyte, Inc. (PCVX): Results of Operations and Financial Condition

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pcvx-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS

SEC EDGAR 8-K6 min
AUG 8
$BPMedAI 8/10

BP Chair Who Sped Up Company’s Turnaround Fired Over Conduct

BP PLC fired Chairman Albert Manifold months after he took the role, citing serious concerns about governance standards, oversight, and conduct, according to BP’s board. BP shares fell about 9.3% after the news, with the stock at 529 pence in London. The move adds to leadership churn as BP seeks a turnaround under CEO Meg O’Neill.

energynow.com4 min
AUG 8
$000660.KSMed

SK Hynix said to mull options for US$3 billion Chongqing plant

SK Hynix is considering options for its Chongqing, China semiconductor packaging and testing facility, including possibly bringing in an investor to accelerate growth. People familiar said a potential stake sale could value the plant at about US$3 billion and SK Hynix may keep a minority stake. Separately, it plans a 54 trillion won (US$38 billion) South Korea expansion for DRAM and NAND.

businesstimes.com.sg3 min
AUG 8
$ZGMed

Zillow Lays Off 500+ Employees Amid $4 Million Q2 Net Loss

Zillow Group said Aug. 4 it will cut more than 500 jobs, about 7% of staff, its second layoff round this year after 200 cuts in January. The company reported Q2 2026 revenue of $772 million, up 18% year over year, but a $4 million net loss driven by a $36 million restructuring charge, citing a flat housing market.

whalesbook.com4 min